Twist Bioscience Reports Strong Q2 Results with Revenue Growth and Path Toward Profitability
Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 second-quarter revenue of $110.7 million, a 19% year-over-year increase, along with an improved adjusted EBITDA loss of approximately $13.3M and gross margin of 51.6%. The company reiterated its path to profitability for Q4 fiscal 2026.
Tickers: $TWST
Topics: aws_partnership cost_reduction ebitda_improvement financial_results revenue_growth